Melanoma
Genasense phase III results in malignant melanoma updated at ASCO
Published in Cancer Weekly, June 21st, 2005
Earlier analyses showed that the addition of Genasense to chemotherapy yielded a statistically significant increase in overall response, complete response, and time-to-progression. Extended follow-up for a minimum of 24 months in all patients has revealed that patients treated with Genasense also achieved a significant increase in "durable" response (i.e., responses longer than 6 months duration) (p=0.02) and a near-significant trend toward increased overall survival (p=0.077).
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-06-21)
More Articles from Cancer Weekly
- Breast Cancer
Breast-conserving surgery compared to mastectomy as primary treatment modality - Doxorubicin
Chronic progressive cardiac dysfunction linked to doxorubicin therapy for ALL - Epstein-Barr Virus
Cancer risk of gastric corpus linked to Epstein-Barr virus infection - Liposarcoma
Gains of 13q correlated with poor prognosis in liposarcoma - Prostate Cancer
High-dose regions linked to likelihood of cure after prostate brachytherapy - Acute Myeloid Leukemia
Wnt/beta-catenin pathway involved in acute myeloid leukemia pathogenesis - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
